As we go to press, shares in Millennium Pharmaceuticals Inc. are slipping again. Thanks to a disappointing set of sales numbers and a relatively small up-front fee from its new partner on the recently launched anticancer drug bortezomib (Velcade), investors are once again wondering whether the company really has figured out how to be a commercial operation, not a discovery company.
But in fact the deal Millennium signed with Johnson & Johnson 's Ortho Biotech Products LP unit—for ex-US...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?